Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) EBT Margin (2023 - 2025)

Mangoceuticals' EBT Margin history spans 3 years, with the latest figure at 9043.49% for Q3 2025.

  • For Q3 2025, EBT Margin fell 754411.0% year-over-year to 9043.49%; the TTM value through Sep 2025 reached 4245.52%, down 301020.0%, while the annual FY2024 figure was 1413.8%, 15440.0% down from the prior year.
  • EBT Margin for Q3 2025 was 9043.49% at Mangoceuticals, down from 3221.61% in the prior quarter.
  • Across five years, EBT Margin topped out at 733.99% in Q3 2023 and bottomed at 9043.49% in Q3 2025.
  • The 3-year median for EBT Margin is 1617.16% (2023), against an average of 2596.31%.
  • The largest annual shift saw EBT Margin skyrocketed 143666bps in 2024 before it crashed -754411bps in 2025.
  • A 3-year view of EBT Margin shows it stood at 1050.87% in 2023, then tumbled by -76bps to 1851.45% in 2024, then crashed by -388bps to 9043.49% in 2025.
  • Per Business Quant, the three most recent readings for MGRX's EBT Margin are 9043.49% (Q3 2025), 3221.61% (Q2 2025), and 4427.47% (Q1 2025).